Back to home » Top Stories » IAC 2010
XVIII International AIDS Conference
IAC 2010 XVIII International AIDS Conference
Reed Messe Wien
Vienna, Austria
July 18-23, 2010

emailprint

5.2 Million People With HIV in Low- and Middle-Income Countries Now on Treatment

July 20, 2010

By Tim Horn

An estimated 5.2 million people in low and middle-income countries were receiving lifesaving HIV treatment at the end of 2009, according to a World Health Organization (WHO) update on Monday, July 19, at the XVIII International AIDS Conference (IAC) in Vienna. 

Since 2003—which marked the launch of the historic “3 by 5” initiative to provide access to HIV treatment to 3 million people living in low- and middle-income countries by the end of 2005—the number of people receiving HIV treatment has increased 12-fold.

WHO estimates that 1.2 million people started treatment in 2009, bringing the total number of people receiving treatment to 5.2 million, compared with 4 million at the end of 2008.

“This is the largest increase in people accessing treatment in a single year. It is an extremely encouraging development,” said Hiroki Nakatani, MD, PhD, the WHO assistant director-general for HIV, Tuberculosis, Malaria and Neglected Tropical Diseases.

At IAC, WHO is calling for earlier treatment for people with HIV, in the form of a 2010 revision to its treatment guidelines. The objective is to begin HIV treatment before they become ill because of weakened immunity.

WHO 2010 HIV Treatment Guidelines  

The World Health Organization's HIV treatment guidelines: "Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach," updated 2010.

 

WHO previously recommended starting HIV treatment when a person’s CD4 count drops below 200 cells, but it now advises starting HIV treatment at 350 cells or below.

“Starting treatment earlier gives us an opportunity to enable people living with HIV to stay healthier and live longer,” said Gottfried Hirnschall, MD, WHO director of HIV/AIDS.

Estimates developed through epidemiological modeling suggest that HIV-related mortality can be reduced by 20 percent between 2010 and 2015 if these guidelines for early treatment are broadly implemented.

Earlier treatment can prevent opportunistic infections including tuberculosis (TB), the No. 1 killer of people with HIV. Deaths from TB can be reduced by as much as 90 percent, Hirnschall suggested, if people with both HIV and TB start treatment earlier.
Along with reductions in morbidity, earlier HIV treatment in low- and middle-income countries will ultimately reduce the costs of hospital care.

Hirnschall also pointed out that earlier treatment might have prevention benefits. “Because treatment reduces the level of virus in the body,” he said, “it means HIV-positive people are less likely to pass the virus on to their partners.”

WHO’s treatment guidelines expand the number of people recommended for HIV treatment from an estimated 10 million to an estimated 15 million. The cost needed for HIV treatment in 2010 will be about $9 billion, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS).

“The investments we make today can save not only millions of lives but millions of dollars tomorrow,” said Bernhard Schwartlander, MD, director, evidence, strategy and results, UNAIDS. “People with weaker immune systems who come late for treatment require more complex and costly drugs and services than those who start treatment earlier and are healthier.”

Unfortunately, the new WHO treatment guidelines are being published just as wealthy nations are reducing support for HIV prevention and treatment programs in low- and middle-income countries. Nakatani, however, stressed that cost should not be a factor in WHO policy. “Guidelines should be evidence-based and should be applicable to anyone—rich or poor.”

Search: antiretroviral, treatment, access, international, global, developing nations, low income, middle income, World Health Organization, Vienna, International AIDS Conference

Scroll down to comment on this story.

emailprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       

More from AIDS2010

HIV/AIDS Complications

July 28, 2010
Global Survey: Stigma, Isolation and Discrimination Still Pervasive
Universal HIV Treatment Access No Guarantee of Health for Socially Disadvantaged
July 27, 2010
OM-85 BV: A Bacterial Vaccine Against Respiratory Problems in People with HIV and COPD?
Low Vitamin D Levels Not Associated With HIV Drugs
July 23, 2010
Longer Duration of HIV Infection Might Increase the Risk of Brain Disorders
Nearly 75 Percent of People With HIV Might Have Bone Problems
July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 21, 2010
Non-AIDS Cancers Occurring at Earlier Age Among People With HIV
Hep C Treatment Effective in HIV Patients With Normal Liver Enzymes
Aging Might Have a Smaller Impact on Immune Function Than Suspected
July 20, 2010
Viramune Boosts Hep C Treatment Efficacy in People With HIV
HIV/HCV Coinfection Further Increases Risk of Bone Fractures
Fewer Malignancies Seen in Those Taking Selzentry

Experimental HIV Drugs

July 23, 2010
More Details of TBR-652’s Antiviral and Anti-Inflammatory Potential Reported
July 22, 2010
ViiV HIV Integrase Inhibitor Performing Well in First-Time Treatment Study
Rilpivirine Has Similar Efficacy and Better Tolerability Than Sustiva
Extended-Release Viramune Has Comparable Safety and Efficacy to Standard Viramune
July 20, 2010
New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains
July 19, 2010
Argos’s Dendritic Cell Therapy Reduces HIV During Treatment Interruption

HIV Transmission and Prevention

July 29, 2010
Prevention Is Failing to Target MSM When They’re Young Enough
July 26, 2010
HPV Cancer Vaccine Effective for Heterosexual, Gay and Bisexual Men
Study Finds PrEP Is Safe in Gay and Bi Men
July 23, 2010
Circumcision Unlikely to Have Major HIV Prevention Benefit Among Gay Men
July 21, 2010
Microbicide Success Story: What It Means and Where We Go Next
MACS: Childhood Sex Abuse and Victimization Linked to Increased HIV Risk
Full-Scale HIV Treatment and Prevention Could Save Millions of Lives
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
HIV Cases in Young People Are Falling Around the World
July 19, 2010
Preliminary Results Suggest Good Safety and Adherence Profile for PrEP

Starting and Switching Treatment

July 22, 2010
Reyataz/Isentress Combo Spares Norvir and Nukes, But Is Integrase Resistance a Concern?
Possibly No Survival Benefit to Starting HIV Treatment at CD4s of 500 or More
Once-Daily Prezista/Norvir Monotherapy Largely Effective Over 96 Weeks
Abacavir/Lamivudine Equivalent to Tenofovir/Emtricitabine in Canadian Cohort Study
July 19, 2010
Strategies for a Cure Reviewed in Vienna
Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment
Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects
Protease Inhibitor-to-Isentress Switch is Effective, Lipid Friendly

Global HIV/AIDS

July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
5.2 Million People With HIV in Low- and Middle-Income Countries Now on Treatment
At Least 31 Countries Deporting People Living With HIV
HIV Cases in Young People Are Falling Around the World


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.